Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.57 |
| ▸ | CKS1B | P61024 | 2/20 | 0.53 |
| ▸ | SKP1 | P63208 | 2/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30712263 | 0.94 | DDB1 (0.56) | DDB1CRBNGPR119CKS1BSKP1 | |
| SCHEMBL25319235 | 0.91 | GPR119 (0.57) | DDB1CRBNGPR119CKS1BSKP1 | |
| SCHEMBL28961480 | 0.85 | DDB1 (0.52) | DDB1CRBNGPR119CKS1BSKP1 | |
| SCHEMBL24964189 | 0.85 | GPR119 (0.61) | DDB1CRBNGPR119CKS1BSKP1 | |
| SCHEMBL29612182 | 0.84 | MAP4K4 (0.60) | DDB1CRBNGPR119CKS1BSKP1 | |
| SCHEMBL265889 | 0.84 | MAP4K4 (0.60) | DDB1CRBNGPR119CKS1BSKP1 | |
| SCHEMBL29890806 | 0.82 | GPR119 (0.60) | DDB1CRBNGPR119CKS1BSKP1 | |
| SCHEMBL1594238 | 0.82 | GPR119 (0.57) | DDB1CRBNGPR119CKS1BSKP1 | |
| SCHEMBL13279435 | 0.82 | GPR119 (0.60) | DDB1CRBNGPR119CKS1BSKP1 | |
| SCHEMBL27848379 | 0.82 | PANK3 (0.54) | HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102239152-B | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP. (JP) | 2014-10-29 | — | — | CN | disclosed |
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| CN-102239152-A | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2011-11-09 | — | — | CN | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010050461-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | 田辺三菱製薬株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | DDB1 4613/4885CRBN 4759/4885GPR119 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.